MiMedx Group Inc (MDXG)
7.455
+0.22
(+2.97%)
USD |
NASDAQ |
May 10, 16:00
7.455
0.00 (0.00%)
After-Hours: 19:50
MiMedx Group Research and Development Expense (Quarterly): 2.841M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.841M |
| December 31, 2023 | -5.503M |
| September 30, 2023 | 3.175M |
| June 30, 2023 | 8.497M |
| March 31, 2023 | 3.484M |
| December 31, 2022 | -4.728M |
| September 30, 2022 | 5.953M |
| June 30, 2022 | 5.512M |
| March 31, 2022 | 5.964M |
| December 31, 2021 | -2.838M |
| September 30, 2021 | 4.368M |
| June 30, 2021 | 4.063M |
| March 31, 2021 | 4.339M |
| December 31, 2020 | 3.434M |
| September 30, 2020 | 3.372M |
| June 30, 2020 | 2.259M |
| March 31, 2020 | 2.65M |
| December 31, 2019 | 2.719M |
| September 30, 2019 | 2.691M |
| June 30, 2019 | 2.828M |
| March 31, 2019 | 2.902M |
| December 31, 2018 | 4.54M |
| September 30, 2018 | 3.962M |
| June 30, 2018 | 3.719M |
| March 31, 2018 | 3.545M |
| Date | Value |
|---|---|
| December 31, 2017 | 3.47M |
| September 30, 2017 | 5.481M |
| June 30, 2017 | 4.747M |
| March 31, 2017 | 4.202M |
| December 31, 2016 | 5.759M |
| September 30, 2016 | 2.919M |
| June 30, 2016 | 3.168M |
| March 31, 2016 | 2.496M |
| December 31, 2015 | 2.341M |
| September 30, 2015 | 2.187M |
| June 30, 2015 | 2.054M |
| March 31, 2015 | 1.831M |
| December 31, 2014 | 1.846M |
| September 30, 2014 | 2.014M |
| June 30, 2014 | 1.80M |
| March 31, 2014 | 1.39M |
| December 31, 2013 | 1.384M |
| September 30, 2013 | 1.287M |
| June 30, 2013 | 0.9245M |
| March 31, 2013 | 1.247M |
| December 31, 2012 | 1.136M |
| September 30, 2012 | 0.8387M |
| June 30, 2012 | 0.5031M |
| March 31, 2012 | 0.4071M |
| December 31, 2011 | 0.6606M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-5.503M
Minimum
Dec 2023
8.497M
Maximum
Jun 2023
2.754M
Average
3.274M
Median
Research and Development Expense (Quarterly) Benchmarks
| TELA Bio Inc | 2.685M |
| Amylyx Pharmaceuticals Inc | 44.91M |
| CEL-SCI Corp | 4.352M |
| AIM ImmunoTech Inc | 3.20M |
| IGC Pharma Inc | 0.903M |